Dallas, TX, May 04, 2016 --(PR.com
)-- Intrauterine contraceptive devices are most commonly known as IUDs/IUCDs. These devices are inserted into the uterus by doctors and other healthcare professionals to prevent contraception, by either immobilizing the sperms on their way to the fallopian tubes or by changing the uterine lining, so that the fertilized egg cannot be implanted in it.
The commonly used IUCD device is a ’T’-shaped device (with horizontal and vertical arms). The vertical arm has a copper wire wrapped around it, as a result of which this device is known as Copper T. In addition, there are two colored nylon threads at the lower end of the horizontal arm. The hormone-releasing IUCDs available in the market are suitable for women with special needs. These devices are 99% reliable in preventing pregnancy. The latest devices, such as LILETTA, Multi Loads ML-Cu-250, ML-Cu-375, and Cu 7 – 380 A, are highly effective, in comparison with the traditional ones.
The global IUCD market is expected to reach a value of $4.4 billion by 2022, at a CAGR of 3.5% from 2016 to 2022. This market is steadily progressing, driven by major factors, such as increasing rate of unplanned pregnancies, growing funds and grants for IUCD product development, and rising awareness regarding contraceptive usage. Furthermore, the rising number of initiatives undertaken by private firms in the emerging markets; favorable insurance for IUCDs; and the one-child policy in some countries have also helped to increase the usage of IUCDs across the globe. However, the high cost of these devices in certain countries; the threat of causing pelvic inflammatory diseases (PID) and ectopic pregnancy; and compulsory assistance of healthcare professionals are among the factors that may restrain the growth of the global IUCDs market in the near future.
The report on the global IUCD market has been segmented and analyzed on the basis of type and geography. On the basis of type, the market has been segmented into copper IUDs/IUCDs and hormonal IUDs/IUCDs. Geographically, the market in Asia accounted for the largest market share of 52.9% of the global intrauterine contraceptive devices market in 2015. The Asian market was valued at $2.21 billion in 2015 and is expected to reach $2.59 billion by 2022, at a CAGR of 2.5% from 2016 to 2022. The IUCD usage in the North American region has been increasing considerably over the past few years, and as a result, the region accounted for the second-largest share of 28.3% in 2015. The North American intrauterine contraceptive devices market was valued at $1.21 billion in 2015 and is expected to reach a value of $1.71 billion by 2022, at a CAGR of 5.1% during the given forecast period.
The key players in the intrauterine contraceptive devices market include Bayer HealthCare AG (A subsidiary of Bayer AG), Teva Pharmaceuticals Industries Ltd., Actavis Plc, Medicines 360, Ocon Medical Ltd., SMB Corporation among others.
For free sample of the report